Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of amylin, a hormone in the body that plays a role in regulating blood sugar and appetite. Activating ...

The agreements covers Zealand's drug, petrelintide, which works by mimicking the amylin hormone. Amylin is co-secreted with insulin. In theory, these drugs could preserve lean muscle mass better than ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

While the obesity field is greatly dominated by GLP-1 products, the amylin hormone is gaining steam as a potential target for treating obesity. It regulates appetite by slowing down stomach ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.

While GLP-1RAs such as semaglutide work by stimulating insulin secretion, reducing glucagon levels, and slowing gastric emptying, amylin analogues such as petrelintide act through a different ...